Proposal to list medical devices supplied by Vantive Limited
What we’re proposing
Pharmac is seeking feedback on a proposal to enter into a medical device listing agreement from 1 April 2026 with Vantive Limited (“Vantive”).
The proposed agreement covers medical devices in the following category:
Consultation closes at 4pm Tuesday 3 February 2026 and feedback can be emailed to julie.crisford@pharmac.govt.nz.
What would the effect be?
From 1 April 2026 medical devices supplied by Vantive in the peritoneal dialysis category would be listed under a national agreement for all Health New Zealand | Te Whatu Ora (“Health NZ”) hospitals to purchase under, subject to consultation and approval by Pharmac’s Board or delegate (“Agreement”).
The Agreement would not be for sole supply and Health NZ hospitals could continue to purchase other supplier’s brands of peritoneal dialysis equipment and consumables.
The Agreement would supersede any existing Health NZ agreements with Vantive for the medical devices included in the Agreement. Any medical devices listed in the Agreement and purchased by Health NZ hospitals would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing on the Pharmaceutical Schedule.
Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by Pharmac.
Who we think will be interested
- Health NZ staff
- Procurement and supply chain personnel
- Renal dialysis staff
- Peritoneal dialysis patients
- Suppliers and Wholesalers
About these medical devices
Peritoneal Dialysis is a type of renal dialysis treatment which uses the peritoneum in a patient’s abdomen as the membrane for fluid exchange. The dialysis fluid is introduced into the patient’s peritoneum and then removed with the waste products absorbed.
This can occur whilst a patient sleeps (automated peritoneal dialysis, APD) or during the day as a patient moves around (Continuous Ambulatory Peritoneal Dialysis, CAPD). The medical devices in this category include the dialysis equipment, fluids that are introduced and the associated consumables such as catheters and preparatory products.
Why we’re proposing this
Pharmac entered into an agreement with Baxter Healthcare Limited in February 2021 for medical devices in the peritoneal dialysis category. In early 2025, Baxter Healthcare Limited divested its kidney care division, resulting in the formation of Vantive Limited(external link). Following this transition, Pharmac has reached an agreement with Vantive to maintain supply under agreed pricing and terms for the New Zealand market.
Details about our proposal
The proposal would result in 81 Peritoneal Dialysis medical devices and consumables being listed on the Pharmaceutical Schedule. The proposal would result in Pharmaceutical Schedule listings of the following brands of medical devices:
|
ARGYLE BIN CURLCATH DIANEAL4 EXTRANEAL EZ-AIDE HCHOICEP |
Medtronic MINICAP OPTICAP PHYSIO40 PTENCKHOFF SWCURLCATH SWPRESCATH |
SWTENCKHOF TENCKHOFF ULTRACLAMP ULTRASET Vantive VEBA |
Further information, including pricing and contractual details, has been provided to Health NZ procurement personnel. Clinicians interested in further detail on what this means for their hospital should engage with their Health NZ procurement teams.
To provide feedback
Send us an email: julie.crisford@pharmac.govt.nz by 4pm Tuesday 3 February 2026.
All feedback received before the closing date will be considered by Pharmac’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
When you give feedback on a consultation, your feedback becomes official information that Pharmac holds. Pharmac has legal responsibilities for how we manage this official information, under laws such as the Official Information Act and Privacy Act.
Pharmac may receive a request from people for official information, which could include your feedback. Legally, Pharmac must consider whether your feedback should be released.
We will consider your views when assessing whether the feedback has to be released. Tell us if there is anything about your feedback that you would prefer wasn’t released.
If your feedback is proposed for release, then Pharmac will contact you, unless there is a legal reason that we can't.
Note that Pharmac collects and holds your information in line with our Privacy Statement.